文献速递慢性肾脏病肾小球疾病

托伐普坦在极低肾功能ADPKD患者中的疗效

Tolvaptan in ADPKD Patients With Very Low Kidney Function.
PubMed 文献 · Kidney Int Rep · 2021-06-09

这项事后分析比较了REPRISE试验中接受安慰剂后转入开放标签扩展试验(OLE)使用托伐普坦的ADPKD患者,以及REPRISE中持续使用托伐普坦的患者。结果显示,在基线eGFR 15-29 ml/min/1.73 m2的患者中,托伐普坦治疗期间的年化eGFR斜率显著优于安慰剂期,差异为1.7 ml/min/1.73 m2(P<0.001)。

要点

  • 托伐普坦可显著延缓eGFR 15-24 ml/min/1.73 m2的ADPKD患者肾功能下降。
  • 在eGFR 25-29 ml/min/1.73 m2患者中同样观察到显著获益。
  • 持续使用托伐普坦的患者治疗效应得以维持。

核心结论

  • 在基线eGFR 15-24和25-29 ml/min/1.73 m2的ADPKD患者中,启动或维持托伐普坦治疗均显著延缓eGFR下降。

研究设计与样本

  • 事后分析,比较REPRISE试验中接受安慰剂后转入OLE使用托伐普坦的患者与REPRISE中持续使用托伐普坦的患者。

主要发现

  • OLE基线eGFR 15-29 ml/min/1.73 m2者,托伐普坦治疗期间年化eGFR斜率为-3.4,安慰剂期为-5.2,差异1.7(P<0.001)。
  • OLE基线eGFR 15-24 ml/min/1.73 m2者,年化eGFR斜率托伐普坦期为-3.6,安慰剂期为-5.4,差异1.8(P<0.001)。
  • OLE基线eGFR 25-29 ml/min/1.73 m2者,年化eGFR斜率托伐普坦期为-3.3,安慰剂期为-4.9,差异1.6(P<0.001)。
  • REPRISE中使用托伐普坦并在OLE中继续使用的患者,治疗效应维持(年化eGFR斜率无差异)。

临床怎么用

  • 对于eGFR 15-29 ml/min/1.73 m2的ADPKD患者,可考虑启动或继续托伐普坦治疗以延缓肾功能下降。

局限性

  • 为事后分析,非随机对照比较,可能存在残余混杂。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: Tolvaptan slowed estimated glomerular filtration rate (eGFR) decline in subjects with autosomal dominant polycystic kidney disease (ADPKD) in TEMPO 3:4 and REPRISE trials. Tolvaptan effects in subjects with eGFR 15 to 24 ml/min per 1.73 m2 were not investigated. This post hoc analysis retrospectively investigated eGFR decline in REPRISE versus an open-label, phase 3b extension trial (open-label extension [OLE] NCT02251275) in subjects who received placebo in REPRISE and tolvaptan in OLE with eGFR 15 to 24 and 25 to 29 ml/min per 1.73 m2, respectively. METHODS: One data subset comprised subjects with OLE baseline eGFR 15 to 29 ml/min per 1.73 m2 who had received placebo in REPRISE and began tolvaptan in OLE. The second comprised subjects who had received tolvaptan in REPRISE and were matched to REPRISE placebo-treated subjects for REPRISE baseline characteristics. Annualized eGFR slopes in REPRISE versus OLE were compared within the REPRISE placebo (i.e., placebo vs. tolvaptan treatment) and tolvaptan (i.e., 2 periods of tolvaptan treatment) subsets. RESULTS: Mean annualized eGFR slopes (ml/min per 1.73 m2) during tolvaptan treatment in OLE versus placebo treatment in REPRISE were -3.4 versus -5.2 for subjects with OLE baseline eGFR 15 to 29 (difference, 1.7; P < 0.001), -3.6 versus -5.4 with baseline eGFR 15 to 24 (difference, 1.8; P < 0.001), and -3.3 versus -4.9 with baseline eGFR 25 to 29 (difference, 1.6; P < 0.001). In REPRISE tolvaptan subjects who continued tolvaptan in OLE, treatment effect was maintained (no difference between mean annualized eGFR slopes). CONCLUSION: Initiating or maintaining tolvaptan therapy significantly delayed eGFR decline in subjects with baseline eGFR 15 to 24 and 25 to 29 ml/min per 1.73 m2.

来源:Kidney Int Rep,查看原文。版权归原作者所有。

引用

  1. Torres VE, Gansevoort RT, Perrone RD, et al. Tolvaptan in ADPKD Patients With Very Low Kidney Function. Kidney Int Rep. 2021. PMID: 34386666. doi:10.1016/j.ekir.2021.05.037

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。